We are pleased to announce the publication of our latest study, “A Bayesian Network Meta-Analysis of Systemic Treatments for Metastatic Castration-Resistant Prostate Cancer in First- and Subsequent Lines,” in the journal Targeted Oncology.
This study represents the largest Bayesian network meta-analysis conducted to date in metastatic castration-resistant prostate cancer (mCRPC), synthesizing data from 43 clinical trials and over 33,000 patients. We evaluated the comparative efficacy of first- and later-line systemic treatments for mCRPC.
Our findings underscore the limited effectiveness of androgen receptor pathway inhibitor (ARPI) re-treatment, likely due to cross-resistance. This reinforces the need for clinical trials aimed at identifying optimal second-line therapies and supporting a class-switching approach in treatment strategies.
Finally, the study highlights key limitations of aggregated data and calls for future research using individual participant data to better capture patient-level heterogeneity. This will be critical to advancing precision medicine and enabling biomarker-driven treatment strategies in mCRPC.
We thank all coauthors for their excellent collaboration!
You can access the full publication here:
https://link.springer.com/article/10.1007/s11523-025-01148-2
Leave a Reply
You must be logged in to post a comment.